(Q40779138)

23 September 2017

A phase-II study of low-dose cyclophosphamide and recombinant human interleukin-2 in metastatic renal cell carcinoma and malignant melanoma (English)

1 reference

metastatic renal cell carcinoma

23 September 2017

0 references

1 reference

A Lindemann

1

1 reference

23 September 2017

K Höffken

2

1 reference

23 September 2017

R E Schmidt

3

1 reference

23 September 2017

V Diehl

4

1 reference

23 September 2017

O Kloke

5

1 reference

23 September 2017

H Gamm

6

1 reference

23 September 2017

J Hayungs

7

1 reference

23 September 2017

W Oster

8

1 reference

23 September 2017

M Böhm

9

1 reference

23 September 2017

J E Kolitz

10

1 reference

23 September 2017

1 January 1989

1 reference

Cancer Immunology, Immunotherapy

23 September 2017

1 reference

23 September 2017

28

1 reference

23 September 2017

275-281

1 reference

23 September 2017

4

1 reference

https://scigraph.springernature.com/pub.10.1007/bf00205237

23 September 2017

0 references

cites work

In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2.

1 reference

12 December 2020

Cachectin: more than a tumor necrosis factor

1 reference

12 December 2020

Successful immunotherapy of mouse melanoma and sarcoma with recombinant interleukin-2 and cyclophosphamide

1 reference

12 December 2020

Soluble interleukin-2 receptor levels in patients with undifferentiated and lymphoblastic lymphomas: correlation with survival

1 reference

12 December 2020

The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo

1 reference

12 December 2020

Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

1 reference

12 December 2020

Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia

1 reference

12 December 2020

Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer.

1 reference

12 December 2020

Hematologic effects of immunotherapy with lymphokine-activated killer cells and recombinant interleukin-2 in cancer patients.

1 reference

12 December 2020

In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy

1 reference

12 December 2020

Specific adoptive therapy of established leukemia with syngeneic lymphocytes sequentially immunized in vivo and in vitro and nonspecifically expanded by culture with Interleukin 2

1 reference

12 December 2020

Multiple biological properties of recombinant human interleukin 1 (beta)

1 reference

12 December 2020

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

1 reference

12 December 2020

In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.

1 reference

12 December 2020

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

1 reference

12 December 2020

Phase I evaluation of recombinant interleukin-2 in patients with advanced malignant disease

1 reference

12 December 2020

Isolation and characterization of lymphokine cDNA clones encoding mouse and human IgA-enhancing factor and eosinophil colony-stimulating factor activities: relationship to interleukin 5.

1 reference

12 December 2020

In vitro effects of 4-hydroperoxycyclophosphamide on human immunoregulatory T subset function. I. Selective effects on lymphocyte function in T-B cell collaboration

1 reference

12 December 2020

Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma [corrected].

1 reference

12 December 2020

Effect of low dose cyclophosphamide on the immune system of cancer patients: reduction of T-suppressor function without depletion of the CD8+ subset

1 reference

12 December 2020

Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells

1 reference

12 December 2020

Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor

1 reference

12 December 2020

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

12 December 2020

Systemic administration of recombinant interleukin 2 stimulates in vivo lymphoid cell proliferation in tissues.

1 reference

12 December 2020

High serum interleukin-2 receptor levels are related to advanced disease and a poor outcome in childhood non-Hodgkin's lymphoma

1 reference

12 December 2020

In vivo interleukin 2 administration augments the generation of alloreactive cytolytic T lymphocytes and resident natural killer cells

1 reference

12 December 2020

The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): implications for the adoptive immunotherapy of tumors

1 reference

12 December 2020

Synergistic effects of combination therapy with human recombinant interleukin-2 and tumor necrosis factor in murine tumor models

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00205237

1 reference

Dimensions Publication ID

23 September 2017

0 references

1 reference